NASDAQ:ALIM - Alimera Sciences Stock Price, Forecast & News

Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALIM stock has decreased by 16.2% and is now trading at $4.39. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alimera Sciences.

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Alimera Sciences.

Alimera Sciences Inc (NASDAQ:ALIM) posted its earnings results on Wednesday, February, 26th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.45. The biopharmaceutical company had revenue of $17.35 million for the quarter, compared to analyst estimates of $14.50 million. View Alimera Sciences' earnings history.

Alimera Sciences shares reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

3 analysts have issued 1 year price targets for Alimera Sciences' shares. Their forecasts range from $15.00 to $45.00. On average, they expect Alimera Sciences' share price to reach $30.00 in the next year. This suggests a possible upside of 583.4% from the stock's current price. View analysts' price targets for Alimera Sciences.

Media coverage about ALIM stock has been trending very positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alimera Sciences earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutAlimera Sciences.

Alimera Sciences saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 20,500 shares, an increase of 9.0% from the February 27th total of 18,800 shares. Based on an average daily volume of 45,300 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.5% of the company's shares are short sold. View Alimera Sciences' Current Options Chain.

Some companies that are related to Alimera Sciences include Zynerba Pharmaceuticals (ZYNE), Cyclerion Therapeutics (CYCN), Inflarx (IFRX), TapImmune (MRKR), ESSA Pharma (EPIX), Chembio Diagnostics (CEMI), Checkpoint Therapeutics (CKPT), Axovant Gene Therapies (AXGT), IDEAYA Biosciences (IDYA), Five Prime Therapeutics (FPRX), PhaseBio Pharmaceuticals (PHAS), Aptorum Group (APM), Clearside Biomedical (CLSD), Monopar Therapeutics (MNPR) and Adamas Pharmaceuticals (ADMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Agenus (AGEN), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Opko Health (OPK), CorMedix (CRMD), Athersys (ATHX) and Gilead Sciences (GILD).

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Alimera Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (4.04%), Renaissance Technologies LLC (1.52%), Royce & Associates LP (0.93%), JW Asset Management LLC (0.55%) and Geode Capital Management LLC (0.21%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko and Richard S Eiswirth Jr. View institutional ownership trends for Alimera Sciences.

ALIM stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Renaissance Technologies LLC, Royce & Associates LP, JW Asset Management LLC, and Geode Capital Management LLC. View insider buying and selling activity for Alimera Sciences.

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALIM stock can currently be purchased for approximately $4.39.

Alimera Sciences has a market capitalization of $21.80 million and generates $53.94 million in revenue each year. The biopharmaceutical company earns $-10,440,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Alimera Sciences employs 124 workers across the globe. View additional information about Alimera Sciences.

The official website for Alimera Sciences is http://www.alimerasciences.com/.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]